NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)--Advaxis, Inc. (OTCBB: ADXS) has signed an agreement with UK based Cobra Biomanufacturing Plc (AIM: CBF) for the manufacturing of its Phase II clinical trial material of a therapeutic cervical cancer vaccine known as Lovaxin C. John Rothman, Vice President, Clinical Development, said, “We look forward to continuing our relationship with Cobra as we move forward with the development of live Listeria vaccines for the treatment of cancer. Our initial clinical work demonstrated the real world utility of our concepts, and Cobra’s ability to execute their production as potential cancer immunotherapeutic agents.”
